Tonix Pharmaceuticals Holding (TNXP) Share-based Compensation (2011 - 2026)

Tonix Pharmaceuticals Holding has reported Share-based Compensation for 16 years, with the latest figure at $2.3 million in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 60.44% year-over-year to $2.3 million in Q2 2026; TTM through Jun 2026 was $2.3 million, a 46.12% decrease from a year earlier, with the FY2025 full-year figure at $12.3 million, up 157.43% from the prior year.
• Share-based Compensation was $2.3 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from $2.1 million in the prior quarter.
• The five-year high for Share-based Compensation was $66.4 million in Q1 2022, with the low at $882000.0 in Q1 2025.
• Average Share-based Compensation over 5 years is $6.3 million, with a median of $2.1 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation jumped 189.08% in 2022, then slumped 90.95% in 2025.
• Over 5 years, Share-based Compensation stood at $2.7 million in 2022, then fell by 24.96% to $2.0 million in 2023, then slumped by 56.13% to $894000.0 in 2024, then surged by 100.11% to $1.8 million in 2025, then increased by 27.62% to $2.3 million in 2026.
• The last three Share-based Compensation figures came in at $2.3 million (Q2 2026), $2.1 million (Q1 2026), and $1.8 million (Q4 2025), per Business Quant data.